---
granola_id: 8910ca29-243d-4824-8c35-c697d1d7aeb4
title: "Virtue VC & FCA VP Catch-up"
type: note
created: 2025-08-25T16:30:20.962Z
updated: 2025-08-28T19:20:34.420Z
attendees:
  - John Orr
  - Andrew Bouldin
---
### Healthcare AI Market & Venture Landscape

- Healthcare VCs “figured out target market fit” - welcome to the party mentality
- Smart DX as prominent example of recent healthcare AI success
- Valuations concerning for companies with 2-4M ARR raising $100M rounds
	- Companies with 10M+ ARR still valuable despite high valuations
- Market evolution: point solutions to platform plays becoming common

### FCA Venture Partners Portfolio & Strategy

- Fund details: investing in software for payers, providers, pharma + innovative care delivery
- Recent investments (4 deals closed):
	- Vellum Health - mobile PICC lines, midlines, IV hydration services
	- Premium - platform connecting community oncologists to experts (redesign deal with Lily contract)
	- Wealth - behavioral economics for medication adherence selling to payers (Mercado led round)
	- Ignite Data - $5M of $10M round
- Sweet spot: 3-7M ARR companies raising 10-15M Series A rounds
- Empiricus standout performer: 14-15M to 40M+ revenue projected this year while profitable

### Virtue VC Fund II Progress & Portfolio Updates

- Fund I: 24 investments, $30M fund, average $890-900k checks
- Fund II: $55M fund, targeting $1.3-1.4M average checks for 10% ownership
- Four investments made in Fund II:
	- Autonomy Health - neurology MSO acquiring practices, in-office infusions
	- Will Johnson’s AI insurance broker rollup (small participation)
	- Dart Health - infrastructure platform for health systems deploying multiple AI use cases
		- Youngest team backed, targeting 10M ARR with 2-3M net income
	- Standard Model Bio - multimodal foundation models for pharma using imaging + genomics data

### Pipeline Companies & Collaboration Opportunities

- Solstice (MLR focus): $3M round at $12.5M post, transitioning from marketing agencies to direct pharma sales
	- 200-400k ACVs per brand expected
- E Tree AI: electronic batch record review for bio manufacturing (pre-seed with Atria Adventures)
- Hermes Health: deidentified data middleware connecting 100% market vs 20% coverage from existing players
- Translucent: ahead of schedule, 2-3M ARR projected by year-end, expanded from medical groups to health systems

### Pharma Tech Investment Outlook

- Remains bullish despite pharma budget corrections
- Real world data spend decrease due to efficiency (buying one Symphony dataset vs five)
- Drug pricing concerns mainly affect MSOs relying on drug margin arbitrage
- Customer concentration risk lower for early-stage companies vs those locked in multi-year contracts

Chat with meeting transcript: https://notes.granola.ai/d/8910ca29-243d-4824-8c35-c697d1d7aeb4
